Patent · US Active

Antibody-drug conjugates (ADCs) of KSP inhibitors with aglycosylated anti-TWEAKR antibodies

US10485880B2 · kind B2 · utility

11Cited by

8References

29Claims

0Family size

Assignee

Bayer Pharma Aktiengesellschaft · DE

Inventors

Hans-Georg Lerchen · Leverkusen, DE
Sven Wittrock · Berlin, DE
Yolanda Cancho Grande · Leverkusen, DE
Beatrix Stelte-Ludwig · Wülfrath, DE
Anette SOMMER · Berlin, DE
Sandra BERNDT · Hohen Neuendorf, DE
Christoph MAHLERT · Wuppertal, DE
Anne-Sophie REBSTOCK · Écully, FR
Carsten TERJUNG · Bochum, DE
Simone Greven · Dormagen, DE

Key dates

Filing date	Dec 10, 2015
Grant date	Nov 26, 2019
Priority date	—
Expiry date	Mar 11, 2036

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61K38/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present application relates to novel binder drug conjugates (ADCs), to active metabolites of these ADCs, to processes for preparing these ADCs, to the use of these ADCs for the treatment and/or prophylaxis of diseases and to the use of these ADCs for preparing medicaments for treatment and/or prophylaxis of diseases, in particular hyperproliferative and/or angiogenic disorders such as, for example, cancer diseases. Such treatments can be effected as monotherapy or else in combination with other medicaments or further therapeutic measures.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.